Neuroimaging in Psychedelic Drug Development | Ebook
How PET and fMRI Can Clarify Mechanisms, Reduce Trial Risk, and Support Regulatory Confidence
Psychedelic drug development presents unique challenges, from functional unblinding and uncertain dosing strategies to the need for objective biomarkers that demonstrate pharmacological activity. As these therapies advance through clinical development, researchers need stronger mechanistic evidence to inform study design, differentiate emerging compounds, and support regulatory confidence.
PET and functional MRI (fMRI) offer valuable tools to address these challenges.
By measuring receptor occupancy, changes in brain connectivity, and treatment-related neural activity, neuroimaging can provide insights into how psychedelic compounds act in the brain and help connect pharmacological effects with clinical outcomes.
In this ebook, Matthew Wall, PhD, Associate Director of Translational MRI at Perceptive Discovery, examines five applications of neuroimaging in psychedelic drug development and explores how integrating molecular and functional imaging into clinical research can strengthen the evidence needed to guide critical development decisions.
What You’ll Learn
- Differentiate Mechanisms of Action: Discover how PET and fMRI can reveal differences in neural activity between psychedelic therapies and conventional antidepressants, even when clinical outcomes appear similar.
- Identify Objective Imaging Biomarkers: Explore how changes in functional connectivity and brain network organization may provide measurable indicators of pharmacological activity and treatment response.
- Optimize Dosing Strategies: Learn how receptor occupancy and the duration of neural effects can inform dose selection, microdosing strategies, and treatment intervals.
- Support Patient Stratification: Understand how baseline neuroimaging measures may help identify patients more likely to respond to treatment and support more targeted clinical trial designs.
- Characterize Next-Generation Psychedelics: Examine how molecular and functional imaging can help researchers evaluate receptor engagement and neural effects in emerging psychedelic compounds and non-hallucinogenic neuroplastogens.
Strengthen Your Approach to Psychedelic Drug Development
Explore how integrating PET and fMRI into psychedelic research can help clarify mechanisms of action, inform clinical study design, and generate objective evidence to support development and regulatory decisions.
Advance CNS Drug Development with Translational Imaging
Generate the evidence needed to make more informed development decisions.
Understanding how a compound interacts with its molecular target and influences brain function is critical to advancing CNS therapeutics.
Perceptive Discovery combines expertise in preclinical and translational CNS imaging, PET and MRI, radiochemistry, and quantitative image analysis to help sponsors characterize drug candidates, evaluate target engagement, and investigate treatment-related changes in the brain.
From early research through clinical translation, our scientific teams work with sponsors to connect imaging insights with development objectives, helping reduce uncertainty and guide critical decisions across the CNS drug development process.